The Patent Finder

Genofocus Co., Ltd.

5 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded as renamed to HLB Genex (2026)

0
Ending by 2030
May 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 12, 2027
    The maintenance fee for Genes encoding alpha-1,3-glucanase and methods of using the same (US 10,472,616) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Jul 7, 2027
    The maintenance fee for Beta-galactosidase variant having high transglycosylation activity, and use thereof (US 10,526,592) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,036,000Beta-galactosidase
In force
 · USPTO record
In forceUSPTO record
US 10,526,592Beta-galactosidase variant having high transglycosylation activity, and use thereof
In force
 · USPTO record
In forceUSPTO record
US 10,472,616Genes encoding alpha-1,3-glucanase and methods of using the same
In force
 · USPTO record
In forceUSPTO record
US 10,751,393Bacillus amyloliquefaciens GF423 strain, and composition for providing antioxidant and anti-inflammatory activities or preventing or treating hyperlipidemia, including polypeptide produced by the same
In force
 · USPTO record
In forceUSPTO record
US 11,147,858Pharmaceutical composition for treating inflammatory bowel disease
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 5: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 1 no status recorded

Showing 1 to 5 of 5, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/724,399Superoxide Dismutase and Uses Thereof for Preventing or Treating Dry Eye SyndromeMay 16, 2022Pending
18/723,214Superoxide Dismutase and Uses Thereof for Preventing or Treating Macular DegenerationMay 16, 2022Pending
18/038,143Nov 23, 2021No status recorded
17/923,296Compositions Comprising Enzymes and Probiotics, and Methods for Preventing or Treating Macular DegenerationMay 5, 2021Pending
17/173,324Compositions and Methods for Preventing or Treating Macular DegenerationFeb 11, 2021Pending
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited